Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

An injection of anti-Rh antibodies (widely known by the trade name RhoGAM) given to the mother soon after birth neutralizes any fetal blood cells in their circulation before their immune system ...

Grifols expects to boost revenue and free cash flow, shares soar Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the ...